The Southeast Cancer Control Consortium, Inc. (SCCC), CCOP has been funded by the National Cancer Institute (NCI) since 1987. The SCCC is a consortium of 20 components/24 institutions in a five-state area of the southeast. The SCCC's long-term objective is to bring state-of-the-art clinical trials to an arena of community institutions to increase access. The catchment of the referral communities is estimated at 8.4 million, with demographics reflecting a low population density, limited socioeconomic and educational development, female percentage greater than 50%, and ratio of African American to white population almost twice the national average. There are 155 participating physicians. Each component has a designated """"""""Community Leader"""""""" (CL) and """"""""Study Coordinator"""""""" (SC) responsible for coordination of the program among participating physicians and the research team. The research team is comprised of oncology nurses and clinical research associates (CRAs) trained by the SCCC Operations Office in compliance to federal and research base (RB) regulations. The SCCC Operations Office coordinates the activities by providing: telephone/fax/email information;website that supplies documents and queries for RBs;Institutional Review Board (IRB) approvals monitoring;RB protocol semimonthly mailings;conduction of component on-site visits;data management training/continuing education programs;preparation of grant applications and reports;and coordination of RB audits. The SCCC Operations Office provides the components with clinical trials from eight RBs. Each component determines the studies applicable to their area and the local IRB, which is authorized by the Office for Human Research Protections (OHRP), grants approval. The CLs and SCs educate and facilitate trial implementation. The expansive network supplies physicians'access to the most advanced level of cancer programs, so patients/participants may access current options. The goal is to reduce morbidity and mortality of cancer by overcoming ethnic, minority, gender, and socioeconomic barriers to clinical trial participation through increasing the number of physicians participating in cancer research with compliance maintained in protocol guidelines.

Public Health Relevance

The mission is to offer access to clinical trials, thus improving the quality of cancer treatment, reducing the incidence through prevention education, and reducing morbidity and mortality through early diagnosis. The opportunity to impart knowledge to minority groups, women, and underserved populations in rural communities increases the chance for these individuals to have comparable medical access.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045808-27
Application #
8540920
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (J1))
Program Officer
Whitman, Cynthia B
Project Start
1987-07-01
Project End
2015-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
27
Fiscal Year
2013
Total Cost
$1,874,946
Indirect Cost
Name
Southeast Cancer Control Consortium
Department
Type
DUNS #
876940532
City
Winston-Salem
State
NC
Country
United States
Zip Code
27104
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-40
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Guercio, Brendan J; Sato, Kaori; Niedzwiecki, Donna et al. (2015) Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol 33:3598-607
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91

Showing the most recent 10 out of 203 publications